Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
The Boston Globe4d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...
StudyFinds on MSN3d
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
Brand-new painkiller approved by US health agency
Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...
AFP5d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...